Occidental Petroleum sits in an unusual position within the American energy landscape, less because of what it does and more because of who watches it. Berkshire Hathaway has accumulated roughly 28 percent of the common equity, holds warrants, and owns preferred stock paying an 8 percent coupon. Warren Buffett rarely concentrates capital in commodity producers, and his sustained accumulation of OXY since 2022 has turned the name into a referendum on long-duration U.S. shale economics. I do not interpret his stake as endorsement. I interpret it as a hypothesis: that domestic barrels with low breakeven costs and disciplined balance sheets become scarcer, not more abundant, over the next decade.
The company operates through three segments that rarely receive equal attention. Oil and Gas is the headline, anchored by a Permian basin position that ranks among the largest in the United States, supplemented by international operations in the Middle East and onshore Gulf of Mexico assets. OxyChem produces chlorine, caustic soda, and PVC, sitting in the top tier of North American chlor-alkali capacity. Midstream and Marketing handles transportation, storage, and the gas processing that ties upstream barrels to end markets. The conglomerate structure is not accidental. It smooths cash flow across cycles in ways a pure-play E&P cannot replicate.
The CrownRock acquisition, closed in 2024 for approximately twelve billion dollars, materially reshaped the upstream footprint. OXY absorbed roughly 170,000 boe/d of high-margin Midland Basin production with sub-forty-dollar breakevens and a deep inventory of undeveloped locations. Synergies were guided at one billion dollars in free cash flow uplift in year one at strip pricing. The cost was leverage. Net debt rose past eighteen billion dollars, and management committed publicly to deleveraging toward fifteen billion before resuming aggressive buybacks. That sequencing matters more than the acquisition itself.
The financial profile today reflects that tension. Shares trade in the mid-forties as of April 2026, within a 52-week range of roughly $40 to $65. Corporate breakeven on oil sits near $40 per barrel including dividend coverage. At $70 Brent, free cash flow generation runs in the four to five billion dollar range annually. The dividend has been rebuilt cautiously after the pandemic-era cut, and buybacks have been throttled to prioritize debt reduction and preferred redemption.
OxyChem deserves more attention than it usually receives. Chlor-alkali economics run countercyclical to oil in meaningful ways, with construction demand, water treatment, and industrial chemicals providing a base of cash generation that does not depend on Brent. In trough oil years, OxyChem has historically contributed one to one and a half billion dollars of EBITDA, a stabilizer that pure E&P names lack.
Carbon management is the segment most exposed to skepticism. The STRATOS direct air capture facility in Texas, developed through 1PointFive, represents the largest commercial DAC project under construction globally. Whether it becomes a durable business or a regulatory artifact depends on 45Q tax credits, voluntary offset markets, and capture cost curves. I treat it as optionality, not a base case.
The dominant variable remains oil. A ten-dollar move in Brent translates roughly to one and a half to two billion dollars in annual free cash flow, given current production volumes. At sustained Brent below $60, the deleveraging timeline extends, buybacks compress, and the preferred coupon becomes a heavier drag. At Brent above $80, the model accelerates and the equity rerates.
Risks cluster around leverage, geopolitics, and energy transition pace. The balance sheet is workable but not forgiving. Middle East exposure is modest but non-zero. Long-dated demand assumptions remain contested. Technically, the chart has built support near $42 and resistance in the $55 to $58 zone, with the mid-forties acting as a battleground for much of the past year.
My read as an observer: OXY is a leveraged bet on domestic shale longevity wrapped inside a chemicals-and-midstream chassis, with a famous shareholder providing implicit patience capital. The thesis works if oil holds a $65 to $80 range and management executes deleveraging without distraction.
What I am watching is not the price. I am watching whether net debt declines on schedule, whether OxyChem margins hold through the construction cycle, and whether STRATOS produces revenue rather than press releases. Those three signals will tell me more about the next five years than any quarterly print.